Skip to content

US · MOLN · BIOTECHNOLOGY

Molecular Partners AG (MOLN) intrinsic value and stock valuation

$2.53as of 2026-11-21 · Mkt cap 151.92M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Molecular Partners AG DCF and intrinsic value

InvestorsCraft values MOLN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MOLN’s statements →

Molecular Partners AG Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Schlieren, ZH 8952 molecularpartners.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-61.65M
20132025
Free cash flow
-$-51.97M
20132025
Total equity
$80.3M-5.6% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$4.97M$7.04M$189.6M$9.33M
Operating income-$-58.12M-$-61.22M-$-61.11M$116.6M-$-63.42M
Net income-$-61.65M-$-54.04M-$-61.98M$117.9M-$-63.78M
EPSd-$-1.65M-$-1.59M-$-1.89M$3.54M-$-2.06M
Operating cash flow-$-51.26M-$-59.25M-$-59.01M$118.6M-$-90.95M
Capital expenditure-$-710K-$-720K-$-570K-$-1.42M-$-1.31M
Free cash flow-$-51.97M-$-59.97M-$-59.81M$117.2M-$-92.26M
Total assets$102.1M$158.5M$198.4M$262.3M$172.7M
Total debt$3.64M$2.44M$3.65M$4.85M$6.04M
Net debt-$-79.01M-$-61.43M-$-63.66M-$-83.1M-$-65.77M
Total equity$80.3M$141.6M$176.4M$235.2M$107.3M
Cash and short-term investments$93.1M$149.4M$186.9M$249.1M$132.8M
Income statement
20252024202320222021
Revenue$0.00$4.97M$7.04M$189.6M$9.33M
Cost of revenue$2.05M$47.5M$47.8M$50.8M$55.7M
Gross profit-$-2.05M-$-42.53M-$-40.81M$138.8M-$-46.39M
Research and development expenses$40.2M$48.6M$48.8M$50.8M$55.7M
Selling, general and administrative expenses$14.9M$17.2M$19M$21.8M$16.9M
Other expenses-$-4.17M-$-47.09M-$-47.48M$370K$120K
Operating expenses$50.9M$18.7M$20.3M$72.9M$72.8M
Cost and expenses$58.1M$66.2M$68.2M$72.9M$72.8M
Interest income$1.52M$3.38M$4.28M$1.2M$110K
Interest expense$20K$30K$50K$650K$610K
Depreciation and amortization$2.14M$2.37M$2.42M$2.39M$2.56M
Ebitda-$-59.49M-$-51.65M-$-59.52M$119M-$-60.66M
Operating income-$-58.12M-$-61.22M-$-61.11M$116.6M-$-63.42M
Total other income/expenses, net-$-3.52M$7.18M-$-880K$1.24M-$-360K
Income before tax-$-61.65M-$-54.04M-$-61.98M$117.9M-$-63.78M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-61.65M-$-54.04M-$-61.98M$117.9M-$-63.78M
Weighted average shares outstanding$37.3M$34M$32.8M$32.5M$31M
Weighted average diluted shares outstanding$37.3M$34M$32.8M$33.3M$31M
Balance sheet
20252024202320222021
Cash and short-term investments$93.1M$149.4M$186.9M$249.1M$132.8M
Net receivables$1.91M$290K$1.75M$1.7M$25.7M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$96.9M$154.3M$192.5M$254.8M$164.2M
Property, plant and equipment, net$5.23M$4.2M$5.68M$7.24M$8.15M
Goodwill and intangible assets$0.00$50K$210K$270K$330K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.23M$4.25M$5.89M$7.51M$8.48M
Total assets$102.1M$158.5M$198.4M$262.3M$172.7M
Accounts payable$940K$680K$410K$1M$4.86M
Short-term debt$1.21M$1.22M$1.21M$1.2M$1.19M
Deferred revenue$0.00$0.00$4.33M$6.41M$28.3M
Total current liabilities$11M$10.8M$14.4M$17.3M$46.9M
Long-term debt$2.44M$1.23M$2.44M$3.65M$4.85M
Deferred revenue, non-current$0.00$0.00$0.00$3.64M$6.92M
Total non-current liabilities$10.8M$6.11M$7.51M$9.84M$18.5M
Capital lease obligations$3.64M$2.44M$3.65M$4.85M$6.04M
Total liabilities$21.8M$16.9M$21.9M$27.1M$65.4M
Common stock$4.04M$4.04M$3.63M$3.6M$3.23M
Retained earnings-$-311.75M-$-246.29M-$-191.75M-$-127.78M-$-250.95M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-980K$0.00
Total equity$80.3M$141.6M$176.4M$235.2M$107.3M
Total investments$10.4M$85.6M$119.6M$161.2M$61M
Total debt$3.64M$2.44M$3.65M$4.85M$6.04M
Net debt-$-79.01M-$-61.43M-$-63.66M-$-83.1M-$-65.77M
Cash flow statement
20252024202320222021
Net income-$-61.65M-$-54.04M-$-61.98M$117.9M-$-63.78M
Depreciation and amortization$2.14M$2.37M$2.42M$2.39M$2.56M
Stock-based compensation$4.42M$4.11M$5.21M$5.09M$4.08M
Change in working capital$1.16M-$-3.8M-$-6.01M-$-6.01M-$-34.67M
Accounts receivable$460K-$-350K-$-930K$25.3M-$-23.37M
Inventory$0.00$0.00$0.00-$-19.93M$21.7M
Accounts payable$60K$520K-$-810K-$-5.34M$1.66M
Net cash provided by operating activities-$-51.26M-$-59.25M-$-59.01M$118.6M-$-90.95M
Investments in property, plant and equipment-$-710K-$-700K-$-810K-$-1.42M-$-1.31M
Acquisitions, net$0.00$0.00$0.00$0.00$370K
Net cash used for investing activities$72.6M$40.5M$44.6M-$-101.12M-$-22.24M
Common stock issued$60K$17.3M$30K$250K$51.5M
Common stock repurchased$0.00$0.00$0.00-$-630K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.15M$14.4M-$-1.17M-$-1.57M$50.6M
Net change in cash$18.8M-$-3.44M-$-20.64M$16.1M-$-61.91M
Cash at end of period$82.7M$63.9M$67.3M$88M$71.8M
Operating cash flow-$-51.26M-$-59.25M-$-59.01M$118.6M-$-90.95M
Capital expenditure-$-710K-$-720K-$-570K-$-1.42M-$-1.31M
Free cash flow-$-51.97M-$-59.97M-$-59.81M$117.2M-$-92.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Molecular Partners AG

        Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

        CEO
        Patrick Amstutz
        Employees
        134
        Beta
        0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of Molecular Partners AG (MOLN)?

        InvestorsCraft does not currently publish an intrinsic value for MOLN. How the IC value is calculated.

        Is MOLN undervalued?

        InvestorsCraft does not publish an undervaluation signal for MOLN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.